Angelo H. Paredes

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

Philip N. Newsome, M. Sasso, Jonathan J Deeks et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 760 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Stephen A. Harrison, Mary E. Rinella, Manal F. Abdelmalek et al. · The Lancet · 2018 · 409 citations

Medicine, Pathology, Pharmacology +17

Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension

Naga Chalasani, Manal F. Abdelmalek, Guadalupe García–Tsao et al. · Gastroenterology · 2019 · 344 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort

Stephen A. Harrison, Samer Gawrieh, Katharine Roberts et al. · Journal of Hepatology · 2021 · 286 citations

Medicine, Endocrinology, Epidemiology +12